Episurf Medical furthers MTP implant preparations by adding Dr. Thomas Roukis, D.P.M., Ph.D. to its Lower Extremity Specialist group
Episurf Medical (Nasdaq: EPIS B) today announces that as it continues development of its MTP implant, the company has added Dr. Thomas Roukis, D.P.M., Ph.D. to its growing list of international Lower Extremity Specialists, joining Prof. Niek van Dijk, MD, Ph.D., and Jouko Kivioja, MD, Ph.D.
Dr. Roukis is Past President (2014-2015) of the 6,800-member American College of Foot & Ankle Surgeons (ACFAS) and is the current Editor-in-Chief of Foot & Ankle Surgery: Techniques, Reports & Cases (FASTRAC). He has served as principal or co-investigator on 22 clinical trials and scientific studies, has published over 175 peer-reviewed scientific articles, and has given more than 425 oral and poster presentations nationally and internationally. Dr. Roukis is board-certified in both foot surgery and reconstructive rearfoot and ankle surgery by the American Board of Podiatric Surgery. Clinically practicing for 20+ years, he was previously an Attending Podiatric Surgeon within the Orthopaedic Service Line at the Gundersen Health System in La Crosse, Wisconsin. Dr. Roukis was also previously Chief of the Limb Preservation Service in the Vascular/Endovascular Surgery Service at the Madigan Army Medical Center in Tacoma, Washington, where he was also Director of the Limb Preservation Complex Lower Extremity Surgery & Research Fellowship. Dr. Roukis received his D. P. M. degree at the California College of Podiatric Medicine, completed Podiatric Medicine & Surgical residency at the Gundersen Health System in La Crosse, Wisconsin, and completed an AO International Trauma Fellowship in Mainz, Germany and a Reconstructive Foot & Ankle Research & Surgery Fellowship in Des Plaines, Illinois
“The problems that Episurf’s foot & ankle products address are common ones that still continue to leave many surgeons looking for answers. Through compelling uses of modern imaging and manufacturing technologies, hopefully we can begin improving longer-term outcomes in these challenging patients,” said Dr. Roukis.
“We are thrilled to be able to work with Dr. Roukis as our lower extremity portfolio continues to take shape in the US. Through our personalized technologies, we have the ability to help many patients delay or avoid end-stage fusion procedures, and Dr. Roukis’ clinical experiences and guidance will help ensure we’re appropriately addressing surgeons’ needs,” said Patrick Jamnik, President of Episurf Medical, Inc.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Tags:
